glp 1 agonists GLP-1 receptor show promise in treating substance use disorders Can one drug do it
Description
Compounded semaglutide/tirzepatide will phase out by late May 2025, so prepare to switch to FDA-approved products
95% CI 0.94, 1.03)
However, the cost of sitagliptin and the need for more data may restrict its use
This systematic review evaluates the literature on the relationship between GLP-1 RA use and increased regurgitation and aspiration events to contextualize the existing, consensus-based guidelines put forth by the ASA in light of limited comparative evidence
These effects extend beyond weight loss, suggesting anti-inflammatory mechanisms with broad potential for managing chronic diseases.
